Upcoming readout of the Keynote-522 trial could open up the neoadjuvant triple-negative breast cancer setting for the Merck & Co drug.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Genkyotex hopes for a reboot with upcoming data on its previously failed lead project, GKT831, in primary biliary cirrhosis.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Roche will find out by September 5 whether its shot at a first-line US lung cancer label has hit the mark.